



Mylan Laboratories Names Hal Korman President of Mylan Pharmaceuticals

PITTSBURGH, May 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the appointment of Hal Korman to the position of President of Mylan Pharmaceuticals, the company's generic subsidiary that develops, manufactures and markets generic pharmaceutical products in a variety of dosage forms. Korman will report to Lou DeBone who had been serving as President of Mylan Pharmaceuticals in addition to his position as President and COO of Mylan Laboratories.

Korman is a 25-year veteran of the pharmaceutical industry. He most recently has been serving as President of UDL Laboratories, Mylan's subsidiary that manufactures and markets unit dose pharmaceutical products. He first joined UDL in 1988 in the sales department, and rapidly progressed to the position of Vice President of Sales. When Mylan acquired UDL in 1996, Korman stayed with the company and was promoted first to Executive Director of Sales and then Vice President of Sales for Mylan Pharmaceuticals. He was promoted to President of UDL in 2001.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented, "Hal has distinguished himself in every stage of his career with UDL and Mylan. Mylan Pharmaceuticals will immediately benefit from his vision, leadership and deep industry knowledge. He is the ideal leader to help drive further growth in our generic pharmaceutical business."

Hal Korman commented, "I am very excited to have this opportunity at a time when the organization is very well positioned for continued success. Mylan's investment in generic research and development over the past several years has paid off with a deep pipeline of generic opportunities. I've also witnessed first hand the incredible culture at Mylan, with a creative, talented, experienced group of people dedicated to identifying, developing and launching innovative generic products."

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

This press release includes statements that constitute "forward-looking statements", including with regard to the anticipated growth and future success of the Company. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effects of vigorous competition on the commercial acceptance of the Company's products and their pricing; the Company's exposure to lawsuits, regulatory and legislative changes and other contingencies associated with its business outside the control of management; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.

05/20/2005

CONTACT: Media, Patrick Fitzgerald, or Investors, Kris King, both of Mylan Laboratories Inc., +1-724-514-1800

Web site: <http://www.mylan.com>